Abstract
Left ventricular assist devices (LVADs) have become an increasingly utilized therapy for advanced heart failure (HF) due to recent innovations in technology, which have led to significantly improved outcomes. With a rapidly aging population in the United States and industrialized world, it is expected that the prevalence and incidence of HF will continue to increase. It is estimated that there are currently between 110,000 and 280,000 adults in the United States alone with NYHA Class IIIB and Class IV HF that could potentially be candidates for LVAD therapy [1]. Currently, <5000 LVAD implants are being performed annually in the US so it appears that this therapy is significantly underutilized.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Heart Disease and Stroke Statistics. Update. American Heart Association. 2014.
Miller LW, Keith AD, Pagani FD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54(4):312–21.
Miller LW, Pagani FD, Russell SD, et al. Use of continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.
Slaughter MS. UNOS status of heart transplant patients supported with left ventricular assist device. Tex Heart Inst J. 2011;38(5):549–51.
Macini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010;122:173–83.
Stevenson LW, Miller LW, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH. Circulation. 2004;110(8):975–81.
Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID trial. J Am Coll Cardiol. 2007;50(8):741–7.
Pagani FD, Patel HJ, Aaronson KD. Significant reduction in major LVAD device failures: comparison of the heartmate VE and XVE LVAD. J Heart Lung Transplant. 2003;22(1):S204.
Rose EA, Geljin AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435–43.
Slaughter MS, Silver MA, et al. Low incidence of neurogenic events during long-term support with the heartmate XVE left ventricular assist device. Tex Heart J. 2008;35(3):245–9.
Arabia FA, Copeland JG, et al. Total artificial hearts: bridge to transplantation. Cardiol Clin. 2003;21(1):101–13.
Kamdar JR, et al. Lessons learned from experience with over 100 consecutive heartmate II left ventricular assist devices. Ann Thorac Surg. 2011;92(5):1593–9.
Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.
LaRose J, Carlos A, et al. Design concepts and principle of operation of the HeartWare ventricular assist system. ASAIO J. 2010;56(4):285–9.
McGee EC, Ahmad U, McCarthy P, et al. Biventricular circulatory support with two miniaturized implantable assist devices. Ann Thorac Surg. 2011;92(1):e1–3.
Aaronson KD, Slaughter MS, et al. Evaluation of the HeartWare HVAD left ventricular assist device system for the treatment of advanced heart failure: results of the ADVANCE bridge to transplant trial. Circulation. 2010;122:2216.
Slaughter MS, Pagani FD, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant. 2013;32(7):675–83.
Copeland J. HeartWare ventricular assist system for bridge to transplant: the new kid on the block. J Heart Lung Transplant. 2013;32(7):671–2.
Boyle A, Kamdar F, John, et al. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg. 2008;86(4):1227–35.
Kirklin JK, Naftel DC, Kormos RL, et al. Second INTERMACS annual report: more than 1000 primary left ventricular assist device implants. J Heart Lung Transplant. 2010;29(1):1–10.
Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support wit h inotropes (COSI) in patients with refractory end stage heart failure. J Card Fail. 2003;9:180–7.
Russell SD, Miller LW, Pagani FD. Advanced heart failure: a call to action. Congestive Heart Fail. 2008;14(6):316–21.
Torre-Amione G, Southard RE, Loebe MM, et al. Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. J Heart Lung Transplant. 2010;29(2):195–200.
Slaughter MS, Pagani FD, Miller LW, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29(4):S1–39.
John R, Pagani FD, Naka Y, Boyle A, et al. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. J Thorac Cardiovasc Surg. 2010;140(1):174–81.
Dang NC, Topkara VK, Mercando M, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant. 2006;25(1):1–6.
Fitzpatrick 3rd JR, Frederick JR, Hiesinger W, et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg. 2009;137(4):971–7.
Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score: a pre-operative toll for assessing the risk of ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163–72.
Fitzpatrick 3rd JR, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant. 2008;27(12):1286–92.
Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007;116:497–505.
Starling RC, Naka Y, Pagani FD, et al. Result of the post-U.S. Food and Drug Administration approved study with a continuous flow left ventricular assist device as a bridge to heart transplantation; a prospective study using the INTERMACS. J Am Coll Cardiol. 2011;57(19):1890–8.
Singh A, Russo MJ, Valeroso TB, et al. Modified HeartMate II driveline externalization technique significantly decreases incidence of infection and improves long-term survival. ASAIO J. 2014. (In press).
Mangi AA. Right ventricular dysfunction in patients undergoing left ventricular assist device implantation: predictors, management, and device utilization. Cardiol Clin. 2011;29(4):629–37.
Starling RC, Silvestry SC, Rogers JG, Milano CA, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370(1):33–40.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag London Ltd.
About this chapter
Cite this chapter
Badami, A.S., Akhter, S.A. (2016). Left Ventricular Assist Devices for Long-Term Circulatory Support. In: Raman, J. (eds) Management of Heart Failure. Springer, London. https://doi.org/10.1007/978-1-4471-4279-9_11
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4279-9_11
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4278-2
Online ISBN: 978-1-4471-4279-9
eBook Packages: MedicineMedicine (R0)